<!DOCTYPE html> <html lang="en"> <head> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <title>Ashkan Pirmani</title> <meta name="author" content="Ashkan Pirmani"/> <meta name="description" content="A simple, whitespace theme for academics. Based on [*folio](https://github.com/bogoli/-folio) design. "/> <meta name="keywords" content="jekyll, jekyll-theme, academic-website, portfolio-website"/> <link href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.1/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha256-DF7Zhf293AJxJNTmh5zhoYYIMs2oXitRfBjY+9L//AY=" crossorigin="anonymous"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/css/mdb.min.css" integrity="sha256-jpjYvU3G3N6nrrBwXJoVEYI/0zw8htfFnhT9ljN3JJw=" crossorigin="anonymous"/> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@5.15.4/css/all.min.css" integrity="sha256-mUZM63G8m73Mcidfrv5E+Y61y7a12O5mW4ezU3bxqW4=" crossorigin="anonymous"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.1/css/academicons.min.css" integrity="sha256-i1+4qU2G2860dGGIOJscdC30s9beBXjFfzjWLjBRsBg=" crossorigin="anonymous"> <link rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700|Roboto+Slab:100,300,400,500,700|Material+Icons"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jwarby/jekyll-pygments-themes@master/github.css" media="none" id="highlight_theme_light"/> <link rel="shortcut icon" href="data:image/svg+xml,<svg xmlns=%22http://www.w3.org/2000/svg%22 viewBox=%220 0 100 100%22><text y=%22.9em%22 font-size=%2290%22>⚛️</text></svg>"> <link rel="stylesheet" href="/assets/css/main.css"> <link rel="canonical" href="https://ashkan-pirmani.github.io/"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jwarby/jekyll-pygments-themes@master/native.css" media="none" id="highlight_theme_dark"/> <script src="/assets/js/theme.js"></script> <script src="/assets/js/dark_mode.js"></script> </head> <body class="fixed-top-nav "> <header> <nav id="navbar" class="navbar navbar-light navbar-expand-sm fixed-top"> <div class="container"> <button class="navbar-toggler collapsed ml-auto" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar top-bar"></span> <span class="icon-bar middle-bar"></span> <span class="icon-bar bottom-bar"></span> </button> <div class="collapse navbar-collapse text-right" id="navbarNav"> <ul class="navbar-nav ml-auto flex-nowrap"> <li class="nav-item active"> <a class="nav-link" href="/">About<span class="sr-only">(current)</span></a> </li> <li class="nav-item "> <a class="nav-link" href="/publications/">Publications</a> </li> <li class="nav-item "> <a class="nav-link" href="/repositories/">Repositories</a> </li> <li class="nav-item "> <a class="nav-link" href="/cv/">Curriculum Vitae</a> </li> <li class="toggle-container"> <button id="light-toggle" title="Change theme"> <i class="fas fa-moon"></i> <i class="fas fa-sun"></i> </button> </li> </ul> </div> </div> </nav> </header> <div class="container mt-5"> <div class="post"> <header class="post-header"> <h1 class="post-title"> <span class="font-weight-bold">Ashkan</span> Pirmani </h1> <p class="desc"><a href="https://www.esat.kuleuven.be/stadius/person.php?id=2346" target="_blank" rel="noopener noreferrer">STADIUS - Department of Electrical Engineering (ESAT) </a> - KU Leuven <br> <a href="https://www.uhasselt.be/en/who-is-who/detail/ashkan-pirmani#" target="_blank" rel="noopener noreferrer">Biomedical Research Institute </a> - Uhasselt</p> </header> <article> <div class="profile float-right"> <figure> <picture> <source class="responsive-img-srcset" media="(max-width: 480px)" srcset="/assets/img/prof_pic-480.webp"></source> <source class="responsive-img-srcset" media="(max-width: 800px)" srcset="/assets/img/prof_pic-800.webp"></source> <source class="responsive-img-srcset" media="(max-width: 1400px)" srcset="/assets/img/prof_pic-1400.webp"></source> <img src="/assets/img/prof_pic.jpg" class="img-fluid z-depth-1 rounded" width="auto" height="auto" alt="prof_pic.jpg" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> <div class="address"> <p>Leuven, Belgium 🇧🇪</p> <p></p> </div> </div> <div class="clearfix"> <p>Ashkan got his master degree in industrial engineering in 2018, and after that, did another master’s in MBA. He started his adventure as a double degree Ph.D student in mid-2019 with the close collaboration of KU Leuven’s STADIUS/ESAT lab and the Biomedical data science research group of Hasselt University in Belgium. He is currently working on federated learning frameworks to apply this framework in health and big data using real-world data. He believes in FAIR data. As “Accessibility” is one of these FAIR data principles, He aims to launch the infrastructures and frameworks that support and learns from other data sources without sacrificing the privacy of real-world data and enabling collaborative learning. He believes we have already passed the centralized data silos era for big data research, and we should come up with ideas to infer how to learn from data, of course, by considering all the ethical and legal challenges. His other research interests are Machine Learning, Collaborative Learning, Decentralization, and MLOps, with a keen interest in containerization and Dashboard Design.</p> </div> <div class="news"> <h2>news</h2> <div class="table-responsive"> <table class="table table-sm table-borderless"> <tr> <th scope="row">Nov 16, 2022</th> <td> This would be honour to present “The use of AI and great real-world data to reveal MS progression: Landscape and future perspectives” at MS Data Alliance Stakeholder Engagement Meeting 2022 (Wednesday 16 November 2022). <br> “The use of Artificial Intelligence and Great Data to reveal progression in MS” is the title of the conferance. This conference would be Baveno Italy 🇮🇹. </td> </tr> <tr> <th scope="row">Sep 6, 2022</th> <td> Super thrilled to announce that my application to attend Oxford Machine Learning Summer School both ML x Health and ML x Finance tracks, in-person, has been successful. <br> So excited to attend this fascinting summer school at Oxford UK 🇬🇧. <br> OxML had an overwhelming number of applicants from 106 countries this year. <a href="https://www.oxfordml.school" target="_blank" rel="noopener noreferrer">More Information</a> </td> </tr> </table> </div> </div> <div class="publications"> <h2>selected publications</h2> <ol class="bibliography"><li> <div class="row"> <div class="col-sm-2 abbr"><abbr class="badge">GDSI</abbr></div> <div id="Simpson-Yape1870" class="col-sm-8"> <div class="title">Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis</div> <div class="author"> Simpson-Yap, Steve, De Brouwer, Edward,  Kalincik, Tomas and <span class="more-authors" title="click to view 44 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '44 more authors' ? 'Rijke, Nick, Hillert, Jan A., Walton, Clare, Edan, Gilles, Moreau, Yves, Spelman, Tim, Geys, Lotte, Parciak, Tina, Gautrais, Clement, Lazovski, Nikola, Pirmani, Ashkan, Ardeshirdavanai, Amin, Forsberg, Lars, Glaser, Anna, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rodden, Salter, Amber, Fox, Robert J., Walt, Anneke, Butzkueven, Helmut, Alroughani, Raed, Ozakbas, Serkan, Rojas, Juan I., Mei, Ingrid, Nag, Nupur, Ivanov, Rumen, Olival, Guilherme, Dias, Alice Estavo, Magyari, Melinda, Brum, Doralina, Mendes, Maria Fernanda, Alonso, Ricardo N., Nicholas, Richard S., Bauer, Johana, Chertcoff, Anı́bal Sebastián, Zabalza, Anna, Arrambide, Georgina, Fidao, Alexander, Comi, Giancarlo, Peeters, Liesbet' : '44 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.text(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, 15); ">44 more authors</span> </div> <div class="periodical"> <em>Neurology</em> 2021 </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a class="bibtex btn btn-sm z-depth-0" role="button">Bib</a> <a href="https://n.neurology.org/content/97/19/e1870" class="btn btn-sm z-depth-0" role="button" target="_blank" rel="noopener noreferrer">HTML</a> <a href="https://n.neurology.org/content/97/19/e1870.full.pdf" class="btn btn-sm z-depth-0" role="button" target="_blank" rel="noopener noreferrer">PDF</a> </div> <div class="abstract hidden"> <p>Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score.Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity.Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.aOR=adjusted OR; BMI=body mass index; CI=confidence interval; COVID-19=coronavirus disease 2019; DMT=disease-modifying therapy; EDSS=Expanded Disability Status Scale; ICU=intensive care unit; MS=multiple sclerosis; MSDA=MS Data Alliance; OR=odds ratio; RRMS=relapsing-remitting MS; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2</p> </div> <div class="bibtex hidden"> <figure class="highlight"><pre><code class="language-bibtex" data-lang="bibtex"><span class="nc">@article</span><span class="p">{</span><span class="nl">Simpson-Yape1870</span><span class="p">,</span>
  <span class="na">author</span> <span class="p">=</span> <span class="s">{Simpson-Yap, Steve and De Brouwer, Edward and Kalincik, Tomas and Rijke, Nick and Hillert, Jan A. and Walton, Clare and Edan, Gilles and Moreau, Yves and Spelman, Tim and Geys, Lotte and Parciak, Tina and Gautrais, Clement and Lazovski, Nikola and Pirmani, Ashkan and Ardeshirdavanai, Amin and Forsberg, Lars and Glaser, Anna and McBurney, Robert and Schmidt, Hollie and Bergmann, Arnfin B. and Braune, Stefan and Stahmann, Alexander and Middleton, Rodden and Salter, Amber and Fox, Robert J. and van der Walt, Anneke and Butzkueven, Helmut and Alroughani, Raed and Ozakbas, Serkan and Rojas, Juan I. and van der Mei, Ingrid and Nag, Nupur and Ivanov, Rumen and Sciascia do Olival, Guilherme and Dias, Alice Estavo and Magyari, Melinda and Brum, Doralina and Mendes, Maria Fernanda and Alonso, Ricardo N. and Nicholas, Richard S. and Bauer, Johana and Chertcoff, An{\'\i}bal Sebasti{\'a}n and Zabalza, Anna and Arrambide, Georgina and Fidao, Alexander and Comi, Giancarlo and Peeters, Liesbet}</span><span class="p">,</span>
  <span class="na">title</span> <span class="p">=</span> <span class="s">{Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis}</span><span class="p">,</span>
  <span class="na">volume</span> <span class="p">=</span> <span class="s">{97}</span><span class="p">,</span>
  <span class="na">number</span> <span class="p">=</span> <span class="s">{19}</span><span class="p">,</span>
  <span class="na">pages</span> <span class="p">=</span> <span class="s">{e1870--e1885}</span><span class="p">,</span>
  <span class="na">year</span> <span class="p">=</span> <span class="s">{2021}</span><span class="p">,</span>
  <span class="na">doi</span> <span class="p">=</span> <span class="s">{10.1212/WNL.0000000000012753}</span><span class="p">,</span>
  <span class="na">publisher</span> <span class="p">=</span> <span class="s">{Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology}</span><span class="p">,</span>
  <span class="na">issn</span> <span class="p">=</span> <span class="s">{0028-3878}</span><span class="p">,</span>
  <span class="na">journal</span> <span class="p">=</span> <span class="s">{Neurology}</span><span class="p">,</span>
<span class="p">}</span></code></pre></figure> </div> </div> </div> </li></ol> </div> <div class="social"> <div class="contact-icons"> <a href="mailto:%61%73%68%6B%61%6E_%70%69%72%6D%61%6E%69@%6F%75%74%6C%6F%6F%6B.%63%6F%6D" title="email"><i class="fas fa-envelope"></i></a> <a href="https://orcid.org/0000-0003-4549-1002" title="ORCID" target="_blank" rel="noopener noreferrer"><i class="ai ai-orcid"></i></a> <a href="https://scholar.google.com/citations?user=RC2DM7kAAAAJ" title="Google Scholar" target="_blank" rel="noopener noreferrer"><i class="ai ai-google-scholar"></i></a> <a href="https://www.researchgate.net/profile/Ashkan-Pirmani/" title="ResearchGate" target="_blank" rel="noopener noreferrer"><i class="ai ai-researchgate"></i></a> <a href="https://github.com/ashkan-pirmani" title="GitHub" target="_blank" rel="noopener noreferrer"><i class="fab fa-github"></i></a> <a href="https://www.linkedin.com/in/ashkan-pirmani-3b8a8896/" title="LinkedIn" target="_blank" rel="noopener noreferrer"><i class="fab fa-linkedin"></i></a> <a href="https://ashkan-pirmani.github.io/feed.xml" title="RSS Feed"><i class="fas fa-rss-square"></i></a> </div> <div class="contact-note"> I would definitely be delighted if you reached out to me using my email or Linkedin. I am sure we will find something to discuss 😊. </div> </div> </article> </div> </div> <footer class="fixed-bottom"> <div class="container mt-0"> © Copyright 2022 Ashkan Pirmani. Powered by <a href="https://jekyllrb.com/" target="_blank" rel="noopener noreferrer">Jekyll</a> with <a href="https://github.com/alshedivat/al-folio" target="_blank" rel="noopener noreferrer">al-folio</a> theme. Hosted by <a href="https://pages.github.com/" target="_blank" rel="noopener noreferrer">GitHub Pages</a>. Photos from <a href="https://unsplash.com" target="_blank" rel="noopener noreferrer">Unsplash</a>. </div> </footer> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.0/dist/jquery.min.js" integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4=" crossorigin="anonymous"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-fgLAgv7fyCGopR/gBNq2iW3ZKIdqIcyshnUULC4vex8=" crossorigin="anonymous"></script> <script src="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/js/mdb.min.js" integrity="sha256-NdbiivsvWt7VYCt6hYNT3h/th9vSTL4EDWeGs5SN3DA=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/masonry-layout@4.2.2/dist/masonry.pkgd.min.js" integrity="sha256-Nn1q/fx0H7SNLZMQ5Hw5JLaTRZp0yILA/FRexe19VdI=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/imagesloaded@4/imagesloaded.pkgd.min.js"></script> <script defer src="/assets/js/masonry.js" type="text/javascript"></script> <script defer src="https://cdn.jsdelivr.net/npm/medium-zoom@1.0.6/dist/medium-zoom.min.js" integrity="sha256-EdPgYcPk/IIrw7FYeuJQexva49pVRZNmt3LculEr7zM=" crossorigin="anonymous"></script> <script defer src="/assets/js/zoom.js"></script> <script defer src="/assets/js/common.js"></script> <script type="text/javascript">window.MathJax={tex:{tags:"ams"}};</script> <script defer type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.0/es5/tex-mml-chtml.js"></script> <script defer src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script> </body> </html>